CXCR2-dependent endothelial progenitor cell mobilization in pancreatic cancer growth

Aihua Li, Xiao J. Cheng, Aune Moro, Rakesh K Singh, Oscar Joe Hines, Guido Eibl

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Neovascularization is essential for tumor growth. We have previously reported that the chemokine receptor CXCR2 is an important regulator in tumor angiogenesis. Here we report that the mobilization of bone marrow (BM)- derived endothelial progenitor cells (EPCs) is impaired in CXCR2 knockout mice harboring pancreatic cancers. The circulating levels of EPCs (positive for CD34, CD117, CD133, or CD146) are decreased in the bone marrow and/or blood of tumor-bearing CXCR2 knockout mice. CXCR2 gene knockout reduced BM-derived EPC proliferation, differentiation, and vasculogenesis in vitro. EPCs double positive for CD34 and CD133 increased tumor angiogenesis and pancreatic cancer growth in vivo. In addition, CD133 + and CD146 + EPCs in human pancreatic cancer are increased compared with normal pancreas tissue. These findings indicate a role of BM-derived EPC in pancreatic cancer growth and provide a cellular mechanism for CXCR2 mediated tumor neovascularization.

Original languageEnglish (US)
Pages (from-to)20-28
Number of pages9
JournalTranslational Oncology
Volume4
Issue number1
DOIs
StatePublished - Jan 1 2011

Fingerprint

Pancreatic Neoplasms
Growth
Bone Marrow
Neoplasms
Knockout Mice
Gene Knockout Techniques
Chemokine Receptors
Endothelial Progenitor Cells
Cell Differentiation
Pancreas
Cell Proliferation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

CXCR2-dependent endothelial progenitor cell mobilization in pancreatic cancer growth. / Li, Aihua; Cheng, Xiao J.; Moro, Aune; Singh, Rakesh K; Hines, Oscar Joe; Eibl, Guido.

In: Translational Oncology, Vol. 4, No. 1, 01.01.2011, p. 20-28.

Research output: Contribution to journalArticle

Li, Aihua ; Cheng, Xiao J. ; Moro, Aune ; Singh, Rakesh K ; Hines, Oscar Joe ; Eibl, Guido. / CXCR2-dependent endothelial progenitor cell mobilization in pancreatic cancer growth. In: Translational Oncology. 2011 ; Vol. 4, No. 1. pp. 20-28.
@article{3c227dcfd6da44168864e8e62a05f878,
title = "CXCR2-dependent endothelial progenitor cell mobilization in pancreatic cancer growth",
abstract = "Neovascularization is essential for tumor growth. We have previously reported that the chemokine receptor CXCR2 is an important regulator in tumor angiogenesis. Here we report that the mobilization of bone marrow (BM)- derived endothelial progenitor cells (EPCs) is impaired in CXCR2 knockout mice harboring pancreatic cancers. The circulating levels of EPCs (positive for CD34, CD117, CD133, or CD146) are decreased in the bone marrow and/or blood of tumor-bearing CXCR2 knockout mice. CXCR2 gene knockout reduced BM-derived EPC proliferation, differentiation, and vasculogenesis in vitro. EPCs double positive for CD34 and CD133 increased tumor angiogenesis and pancreatic cancer growth in vivo. In addition, CD133 + and CD146 + EPCs in human pancreatic cancer are increased compared with normal pancreas tissue. These findings indicate a role of BM-derived EPC in pancreatic cancer growth and provide a cellular mechanism for CXCR2 mediated tumor neovascularization.",
author = "Aihua Li and Cheng, {Xiao J.} and Aune Moro and Singh, {Rakesh K} and Hines, {Oscar Joe} and Guido Eibl",
year = "2011",
month = "1",
day = "1",
doi = "10.1593/tlo.10184",
language = "English (US)",
volume = "4",
pages = "20--28",
journal = "Translational Oncology",
issn = "1936-5233",
publisher = "Neoplasia Press",
number = "1",

}

TY - JOUR

T1 - CXCR2-dependent endothelial progenitor cell mobilization in pancreatic cancer growth

AU - Li, Aihua

AU - Cheng, Xiao J.

AU - Moro, Aune

AU - Singh, Rakesh K

AU - Hines, Oscar Joe

AU - Eibl, Guido

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Neovascularization is essential for tumor growth. We have previously reported that the chemokine receptor CXCR2 is an important regulator in tumor angiogenesis. Here we report that the mobilization of bone marrow (BM)- derived endothelial progenitor cells (EPCs) is impaired in CXCR2 knockout mice harboring pancreatic cancers. The circulating levels of EPCs (positive for CD34, CD117, CD133, or CD146) are decreased in the bone marrow and/or blood of tumor-bearing CXCR2 knockout mice. CXCR2 gene knockout reduced BM-derived EPC proliferation, differentiation, and vasculogenesis in vitro. EPCs double positive for CD34 and CD133 increased tumor angiogenesis and pancreatic cancer growth in vivo. In addition, CD133 + and CD146 + EPCs in human pancreatic cancer are increased compared with normal pancreas tissue. These findings indicate a role of BM-derived EPC in pancreatic cancer growth and provide a cellular mechanism for CXCR2 mediated tumor neovascularization.

AB - Neovascularization is essential for tumor growth. We have previously reported that the chemokine receptor CXCR2 is an important regulator in tumor angiogenesis. Here we report that the mobilization of bone marrow (BM)- derived endothelial progenitor cells (EPCs) is impaired in CXCR2 knockout mice harboring pancreatic cancers. The circulating levels of EPCs (positive for CD34, CD117, CD133, or CD146) are decreased in the bone marrow and/or blood of tumor-bearing CXCR2 knockout mice. CXCR2 gene knockout reduced BM-derived EPC proliferation, differentiation, and vasculogenesis in vitro. EPCs double positive for CD34 and CD133 increased tumor angiogenesis and pancreatic cancer growth in vivo. In addition, CD133 + and CD146 + EPCs in human pancreatic cancer are increased compared with normal pancreas tissue. These findings indicate a role of BM-derived EPC in pancreatic cancer growth and provide a cellular mechanism for CXCR2 mediated tumor neovascularization.

UR - http://www.scopus.com/inward/record.url?scp=79251553195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251553195&partnerID=8YFLogxK

U2 - 10.1593/tlo.10184

DO - 10.1593/tlo.10184

M3 - Article

VL - 4

SP - 20

EP - 28

JO - Translational Oncology

JF - Translational Oncology

SN - 1936-5233

IS - 1

ER -